Serial Number | 79308937 |
Word Mark | DEEPZEMA AI-AUGMENTED DRUG DISCOVERY |
Filing Date | Tuesday, February 23, 2021 |
Status | 700 - REGISTERED |
Status Date | Tuesday, May 24, 2022 |
Registration Number | 6720808 |
Registration Date | Tuesday, May 24, 2022 |
Mark Drawing | 5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
Published for Opposition Date | Tuesday, February 22, 2022 |
Description of Mark | The mark consists of the term "DEEPZEMA" in red font above the wording "AI-AUGMENTED DRUG DISCOVERY" in black font. The color white represents background, shading and/or transparent areas and is not claimed as a feature of the mark. |
Description of the Colors Claimed | The color DARK RED appears in the word 'DeepZema', and the color BLACK appears in the word 'AI-augmented Drug Discovery'. |
Indication of Colors claimed | The colors dark red and black is/are claimed as a feature of the mark. |
Disclaimer with Predetermined Text | "DRUG DISCOVERY" |
Goods and Services | Medicine research; research of pharmaceuticals; drug discovery services; research of crude medicines; research of medicines; research service of pharmaceuticals; development of pharmaceuticals and drugs; clinical trial; conducting clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy in the field of testing, inspection, research of medical products; conducting early evaluations in the field of new pharmaceuticals; development of biotechnology |
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Friday, April 16, 2021 |
Primary Code | 042 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Party Name | Innovo Therapeutics Inc. |
Party Type | 30 - Original Registrant |
Legal Entity Type | 99 - Other |
Address | KR |
Party Name | Innovo Therapeutics Inc. |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 99 - Other |
Address | KR |
Party Name | Innovo Therapeutics Inc. |
Party Type | 10 - Original Applicant |
Legal Entity Type | 99 - Other |
Address | KR |
Event Date | Event Description |
Sunday, October 2, 2022 | FINAL DECISION TRANSACTION PROCESSED BY IB |
Saturday, September 10, 2022 | FINAL DISPOSITION NOTICE SENT TO IB |
Friday, September 9, 2022 | FINAL DISPOSITION PROCESSED |
Wednesday, August 24, 2022 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
Tuesday, May 24, 2022 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
Tuesday, May 24, 2022 | REGISTERED-PRINCIPAL REGISTER |
Tuesday, February 22, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Tuesday, February 22, 2022 | PUBLISHED FOR OPPOSITION |
Sunday, February 20, 2022 | NOTIFICATION PROCESSED BY IB |
Wednesday, February 2, 2022 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
Wednesday, February 2, 2022 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
Wednesday, February 2, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Tuesday, January 18, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Thursday, January 13, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Wednesday, January 12, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Wednesday, January 12, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Monday, November 15, 2021 | REFUSAL PROCESSED BY IB |
Sunday, October 24, 2021 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
Friday, October 15, 2021 | REFUSAL PROCESSED BY MPU |
Tuesday, September 28, 2021 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
Monday, September 27, 2021 | NON-FINAL ACTION WRITTEN |
Friday, September 17, 2021 | ASSIGNED TO EXAMINER |
Tuesday, April 20, 2021 | APPLICATION FILING RECEIPT MAILED |
Friday, April 16, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
Thursday, April 15, 2021 | SN ASSIGNED FOR SECT 66A APPL FROM IB |